To reach the next value inflection
LicenseRx asset brief
Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties
Probability of Success
24% · grade C · Medium data confidence
Model PoS 24% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.
Data maturity (22%)
59
Preclinical; human data.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
76
Neurology -- active buyer appetite.
Competitive whitespace (12%)
74
Multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: human.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →